Connect with us

Market News

SEER Stocks Price Increased by 8.95% : Here’s what Happened

Published

on

Seer, Inc. (NSDQ:SEER) ‘s stock prices increased by 8.95%% on 5th April 2021. The price dropped from $56.94 to $52.18 between 2nd to 4th April and hiked from $52.18 to $56.85. The prices have been fluctuating for the last five days. 

Omid Farokhzad, Chairman, Chief Executive Officer, and Founder, said “ Today marks our first earnings call at the public company. This is a seminal milestone for our company and a particularly gratifying one for me as the founder of Seer. We will begin today’s call with an overview of our opportunity and our strategy.

We will then transition our comments to provide a review of our progress in 2020 and a preview of our objectives for 2021. Seer has gone from setting our initial vision of enabling broad-scale access to deepen [Inaudible] proteomics to shipping products to our customers in just three short years. We have built a world-class team that is second to none in the proteomics space, and we have a product solution that is well-positioned to enable the kind of proteomic studies that were just not possible before Seer. To our incredible team, I would like to take a moment and express my sincere thanks to each and every one of you for your passion, dedication, and hard work.”

David Horn, the chief financial officer of Seer, Inc. (NSDQ:SEER) added, “We completed a research collaboration study with a partner in 2020. To date, all of our revenue has been generated from grant-funded activities and research collaborations with biopharma companies, and we have not generated any revenue from product sales. Total operating expenses for the fourth quarter of 2020 were $13.4 million, compared to $5.5 million in the fourth quarter of 2019. Total operating expenses for 2020 were $34.3 million, compared to $17 million in 2019.

Research and development expenses for the fourth quarter of 2020 were $5.4 million, compared to $3.8 million in the fourth quarter of 2019. Research and development expenses for 2020 were $18.9 million, compared to $12.4 million in 2019. The increase in R&D expenses for the year was primarily driven by increased product development efforts related to our Proteograph Product Suite, including an increase in research and development personnel. General and administrative expenses for the fourth quarter of 2020 were $8 million, compared to $1.6 million in the fourth quarter of 2019.

G&A expenses for the year were $15.4 million, compared to $4.6 million 2019. The increase in G&A expenses for the year was primarily driven by increased headcount and associated compensation expenses, including stock-based compensation, as well as increased costs related to becoming a public company. Net loss for the fourth quarter was $12.9 million, compared to $5.1 million in the fourth quarter of 2019. Net loss for the full year was $32.8 million, compared to $16 million in 2019.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Market News

BCRX’s Stock Price News: 11.29% Increase!

Published

on

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)’ stock price increased by 11.29% over the previous closing price, 10.19(April 14) and currently stands at 11.34. The volume on April 15 was pretty high, 8,433,333. Day’s range- 10.13 – 11.57. 

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)’s stock prices for the last 5 days-

Date Open High Low Close
Apr 15, 2021 10.31 11.58 10.13 11.34
Apr 14, 2021 9.79 10.64 9.72 10.19
Apr 13, 2021 9.59 9.73 9.23 9.69
Apr 12, 2021 10.15 10.16 9.34 9.50
Apr 09, 2021 10.38 10.56 10.19 10.21

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) yesterday announced that the Japanese National Health Insurance System (NHI) has approved the addition of oral, once-daily ORLADEYO™ (berotralstat) to the NHI drug price list on April 21, 2021.

Oral, once-daily ORLADEYO was approved in Japan in January 2021 for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan.

“Our goal is to bring ORLADEYO to HAE patients around the world who want a new oral, once-daily option to prevent their attacks. In Japan, ORLADEYO is the first approved prophylactic HAE medication, which has the potential to significantly impact the lives of HAE patients,” said Jon Stonehouse, president and chief executive officer of BioCryst.

The NHI price listing triggers a $15 million milestone payment from Torii to BioCryst. In addition, BioCryst will receive tiered royalties ranging from 20 percent to 40 percent of Japanese net sales.

About ORLADEYO™ (berotralstat)

ORLADEYO™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

Continue Reading

Market News

BTG Stock Price News: 6.41% Increase

Published

on

B2Gold Corp. (NYSEAMERICAN: BTG)’s stock price stands at 4.9800 At close: 4:00PM EDT, April 15. The opening price was 4.7800 and the previous closing price, as of April 14, was 4.6800. The price increased by 0.3000. Day’s range- 4.7700 – 5.0222.

B2Gold Corp. (NYSEAMERICAN: BTG)’s stock price is currently at the month’s highest. The highest price of the day(April 15)  was 5.0200 and the lowest was 4.7700. 

B2Gold is a low-cost international senior gold producer headquartered in Vancouver, Canada. Founded in 2007, today, B2Gold has operating gold mines in Mali, Namibia and the Philippines and numerous exploration and development projects in various countries including Mali and Colombia. B2Gold continues to forecast total consolidated gold production of between 970,000 and 1,030,000 ounces in 2021. 

Mine-by-mine gold production in the first quarter of 2021 (including the Company’s estimated 33% share of Calibre’s production) was as follows:

Mine Q1 2021

Gold Production

(ounces)

First-Half 2021

Forecast

Gold Production

(ounces)

Second-Half

2021 Forecast

Gold Production

(ounces)

Full-year

2021 Forecast

Gold Production

(ounces)

Fekola 125,088 220,000 – 230,000 310,000 – 330,000 530,000 – 560,000
Masbate 57,513 100,000 – 105,000 100,000 – 105,000 200,000 – 210,000
Otjikoto 23,042 45,000 – 50,000 145,000 – 150,000 190,000 – 200,000
B2Gold Consolidated (1) 205,643 365,000 – 385,000 555,000 – 585,000 920,000 – 970,000
Equity interest in Calibre (2) 15,001 25,000 – 30,000 25,000 – 30,000 50,000 – 60,000
Total 220,644 390,000 – 415,000 580,000 – 615,000 970,000 – 1,030,000

 

1 “B2Gold Consolidated” – gold production is presented on a 100% basis, as B2Gold fully consolidates the results of its Fekola, Masbate and Otjikoto mines in its consolidated financial statements (even though it does not own 100% of these operations).
2 “Equity interest in Calibre” – represents the Company’s approximate 33% indirect share of the operations of Calibre’s El Limon and La Libertad mines. B2Gold applies the equity method of accounting for its 33% ownership interest in Calibre.
Continue Reading

Market News

HBM Stock Price Increased By 6.72%: Here’s What Happened

Published

on

Hudbay Minerals Inc. (NYSE: HBM)’s stock price currently stands at 8.42, as of April 15, 4:00PM EDT, market close. The previous closing price was 7.89(April 14). Thus, a surge of 6.72% is significant. The day’s range was between 7.98 – 8.51. 

Hudbay (NYSE: HBM) is a diversified mining company primarily producing copper concentrate (containing copper, gold and silver) and zinc metal. Hudbay (NYSE: HBM)’s stock price is grossing at its highest price of this month, the second highest price being 8.06( Closing price April 8).

Hudbay Minerals Inc. (NYSE: HBM) today announced that the final land user agreement for Pampacancha has been completed and Hudbay now has full access to the site to begin pit development activities.

“We are very pleased to have completed the final land user agreements at Pampacancha and we remain on track for first production in the second quarter of 2021, in line with guidance,” said Peter Kukielski, Hudbay’s President and Chief Executive Officer. “This major milestone was achieved due to collaboration between the community and the Constancia team, which further demonstrates Hudbay’s strong social license to operate in Peru.”

In January 2021, the company commenced pre-development activities, including haul road construction and site preparation work, which will allow Hudbay to commence pre-stripping activities shortly. Pampacancha is a high-grade copper and gold satellite deposit located approximately seven kilometres from Hudbay’s Constancia mine and processing facilities in Peru. Pampacancha is expected to contribute to an increase in copper and gold production at Constancia from 2022 to 2025 as the higher grades enter into the mine plan.

Continue Reading

Trending